secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-275461
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta completes merger with Cartesian; renamed Cartesian Therapeutics, ticker RNAC
--------------------------------------------------------------------------------

- Merger closed Nov 13; Selecta issued 6.7M common shares and 384,931 Series A Preferred to Cartesian holders.
- Insider PIPE of $60.25M from board member Springer and former CEO Kalayoglu trust; 149,330 Series A Preferred sold.
- New officers appointed: Metin Kurtoglu (COO), Milos Miljkovic (CMO), Chris Jewell (CSO); former CMO/CSO/COO resigned.
- CVRs to be issued to Selecta stockholders, entitling them to 100% of future Sobi license milestones/royalties.
- Series A Preferred convertible into 1,000 common shares each, subject to stockholder approval of charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-275461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer